Yosuke Aoyama, Eri Hoshino, Akihiko Shimomura, Chikako Shimizu, Tomoko Taniyama, Manami Tada, Nao Yoshida, Hitomi Sato, Kiyomi Nonogaki, Kazumasa Yamamoto, Taro Yamanaka, Rika Kizawa, Takeshi Yamaguchi, Kiyo Tanaka, Yoko Kobayashi, Nobuko Tamura, Yuko Tanabe, Yuji Miura, Yuichiro Kikawa, Juhee Cho, Hidetaka Kawabata
Breast cancer (Tokyo, Japan) 2024 MarThe Chemotherapy-induced Alopecia Distress Scale (CADS) is a patient-reported outcome measure for assessing distress associated with Chemotherapy-induced alopecia (CIA). This study aimed to confirm the psychometric validity of the Japanese version of the CADS (CADS-J). A total of 132 patients with breast cancer who developed CIA were asked to complete the CADS-J twice at 2 week intervals to confirm test-retest reliability. The body image domain of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) breast cancer-specific module, the self-esteem scale from the Rosenberg Self-Esteem Scale, and the emotional domain of the EORTC QLQ Core 30 were used to confirm the convergent validity of the CADS-J. The overall quality of life and physical domains of the EORTC QLQ Core 30 were used to confirm the discriminant validity of the CADS-J. In total, 125 participants provided valid responses. The mean age was 52.2 years. The overall Cronbach's alpha for the CADS-J was 0.903. The intraclass correlation coefficients of the first and second responses were r = 0.874, r = 0.952, r = 0.911, and r = 0.959 for the physical domain, emotional domain, activity domain, and relationship domain, respectively. In terms of convergent validity, the total CADS-J score was moderately correlated with body image (r = - 0.63), self-esteem (r = - 0.48), and the emotional domain (r = - 0.61). Regarding discriminant validity, the total CADS-J score was weakly correlated with the overall quality of life (r = - 0.34) and physical domain (r = - 0.24). The CADS-J is psychometrically reliable and valid for evaluating the distress caused by CIA. It is expected to be used in daily practice and as an endpoint in various studies. © 2023. The Author(s), under exclusive licence to The Japanese Breast Cancer Society.
Yosuke Aoyama, Eri Hoshino, Akihiko Shimomura, Chikako Shimizu, Tomoko Taniyama, Manami Tada, Nao Yoshida, Hitomi Sato, Kiyomi Nonogaki, Kazumasa Yamamoto, Taro Yamanaka, Rika Kizawa, Takeshi Yamaguchi, Kiyo Tanaka, Yoko Kobayashi, Nobuko Tamura, Yuko Tanabe, Yuji Miura, Yuichiro Kikawa, Juhee Cho, Hidetaka Kawabata. Reliability and validity of the Japanese version of the Chemotherapy-induced Alopecia Distress Scale. Breast cancer (Tokyo, Japan). 2024 Mar;31(2):234-242
PMID: 38079066
View Full Text